ALK Actualización en terapias dirigidas en CPNM ALK+

22 / 48

ACTIVITY OF ALK INHIBITORS IN CRIZOTINIB TREATED PATIENTS
Drug Study RR mPFS
Ceritinib1,2,3 Phase I ASCEND-1
Phase II ASCEND-2
Phase III ASCEND-5
56%
38.6%
39.1%
6.9m
5.7m
5.4m
Alectinib 4--7 Phase I/II AF-001JP
Phase II NP28761
Phase II NP28673
Phase III ALUR
55%
52%
50%
37.5%
NA
8.2m
8.9m
9.6m
Brigatinib8 Phase I/II 55% 15.6m
Lorlatinib9,10 Phase I
Phase II
42-46%
69%
9.2-13.5m
Not Reached
Ensartinib11 Phase I/II 69% 9m
1. Kim DW et al. Lancet Oncol 2016 2. Mok T et al. J Clin Oncol 2015 Abstr 8059. 3. Shaw A et al. Lancet Oncol 2017. 4-Seto T et al.
Lancet Oncol 2013. 5-Shaw A et al. Lancet Oncol 2016. 6-Ou SH et al. J Clin Oncol 2016. 7- Novello S, et al. ESMO 2017.
8- Bazhenova et al. ESMO 2016. 9 Shaw A, et al. Lancet Oncol 2017. 10-Ahn W et al. WCLC 2017. 11- Horn L, et al. Clin Cancer